title: Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab.
abstract: Treatment of widespread moderate to severe atopic eczema remains a challenge. The therapeutic efficacy and modifications of the immune response during treatment of atopic eczema with efalizumab are so far unknown. We hereby report the clinical findings and characterize the inflammatory infiltrate during treatment of severe recalcitrant atopic eczema with efalizumab.
authors.affiliation: Department of Dermatology, University of Bern, Inselspital, Switzerland.
authors.forename: Akmal S
authors.initials: AS
authors.lastname: Hassan
authors.forename: Ursula
authors.initials: U
authors.lastname: Kaelin
authors.forename: Lasse Roger
authors.initials: LR
authors.lastname: Braathen
authors.forename: Nikhil
authors.initials: N
authors.lastname: Yawalkar
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens / Q000276:immunology; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008264:Macrophages / Q000276:immunology; D008297:Male; D012867:Skin / Q000276:immunology / Q000473:pathology
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens; C472181:efalizumab